ST Notech announced that it recently received its CBPF-GMP certificate, issued by the Brazilian National Health Surveillance Agency (ANVISA), a member of the PIC/S (Public Health and Medical Products Administration). This inspection covered the company's Lianyungang facility's cGMP system, which produces the APIs semaglutide and liraglutide. This on-site cGMP inspection by ANVISA marks the first time the company's semaglutide and liraglutide API production lines have passed official overseas compliance inspections, following those by the U.S. Food and Drug Administration (FDA) and the Ministry of Food and Drug Safety (MFDS) of South Korea.